Guanethidine treatment does not block the ability of central leptin administration to decrease blood glucose concentrations in streptozotocin-induced diabetic rats

Jinpin Wang¹, Catherine M Wernette¹, Robert L Judd², Kevin W Huggins¹ and B Douglas White¹

Departments of ¹Nutrition and Food Science and ²Anatomy, Physiology and Pharmacology, Auburn University, Auburn, Alabama 36849, USA

(Correspondence should be addressed to B.D White; Email: whitebd@auburn.edu)

Abstract

Leptin, administered either into the ventricles of the brain or systemically, has been shown to normalize blood glucose concentrations in streptozotocin (STZ)-induced diabetic rats. We hypothesized that an intact sympathetic nervous system is necessary for centrally administered leptin to normalize or attenuate high blood glucose concentrations in STZ-induced diabetic rats. Young male Wistar rats (~50 g) were treated every other day with either s.c. guanethidine (100 mg/kg) or vehicle for 2 weeks. Rats were then implanted with an intracerebroventricular cannula directed to the lateral ventricle and made diabetic with an i.v. injection of STZ (50 mg/kg). Half of the animals in each group were given daily injections of leptin (10 μl), while the remaining animals received vehicle injections. Blood glucose concentrations were measured daily and tissue norepinephrine content was determined by high performance liquid chromatography at the end of the study. Guanethidine pretreatment did not block the ability of centrally administered leptin to decrease blood glucose concentrations in diabetic rats. This suggests that the sympathetic nervous system does not mediate the leptin-induced attenuation of high blood glucose concentrations observed in diabetic rats.


Introduction

Chronic peripheral leptin administration (via subcutaneous osmotic pump) normalizes blood glucose concentrations in streptozotocin (STZ)-induced diabetic rats (Chinookoswong et al. 1999). This is associated with a decrease in the rate of glucose production under basal and hyperinsulinemic conditions, and an increase in whole-body glucose utilization during insulin infusion. Central leptin administration over a period of several days also normalizes blood glucose concentrations in STZ-induced diabetic rats (Hidaka et al. 2002, Lin et al. 2002, da Silva et al. 2006). Several lines of evidence suggest that leptin acts centrally to cause these effects. Central injections of leptin normalize blood glucose concentrations without increasing the serum leptin concentration (Hidaka et al. 2002, Lin et al. 2002), and the dose of leptin that normalizes blood glucose concentrations when injected centrally has no effect when injected systemically (Hidaka et al. 2002). Pair-feeding studies show that the effect of leptin on blood glucose is not secondarily due to a decrease in feeding (Hidaka et al. 2002, Lin et al. 2002). Also, the administration of central leptin does not increase serum insulin concentrations (Hidaka et al. 2002, Lin et al. 2002). In fact, central leptin administration decreases serum insulin concentrations in nondiabetic rats to the level found in STZ-treated rats (Dobbins et al. 2002, Lin et al. 2002). The mechanism by which central leptin normalizes blood glucose concentrations in STZ-induced diabetic rats is not clear.

One of the reported effects of central leptin is activation of the sympathetic nervous system. Direct nerve recordings have shown that i.v. leptin administration stimulates sympathetic activity in the kidney, adrenal glands, and hind limbs (Haynes et al. 1997). The time course of the response and lack of a dose–response to circulating leptin concentrations suggest that sympathetic activation by leptin is at least partially mediated by the central nervous system (Haynes et al. 1997). Indeed, lesions of the arcuate nucleus of the hypothalamus abolish the sympathetic response to systemic infusion of leptin (Haynes 2000). Hypothalamic leptin administration increases glucose uptake in heart, brown adipose tissue, and soleus and extensor digitorum longus muscles (Haque et al. 1999). The increase in glucose uptake in these tissues is blocked by prior treatment with guanethidine, suggesting that leptin-mediated glucose uptake into these tissues requires the sympathetic nervous system. Activation of AMP-dependent protein kinase (AMPK) increases glucose uptake in skeletal muscle (Merrill et al. 1997). Intrahypothalamic injections of leptin increase the activity of AMPK in skeletal muscle (Minokoshi et al. 2002). This effect is blocked by surgical disruption of sympathetic innervation to the muscle or by blockade of α-adrenergic.
receptors, suggesting that the sympathetic nervous system mediates the central effects of leptin on AMPK activation in muscle (Minokoshi et al. 2002). Infusion of 5-aminimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), a stimulator of AMPK activity, not only increases glucose uptake (Merrill et al. 1997) and oxidation (Smith et al. 2005) in skeletal muscle, but also decreases endogenous glucose production rates (Bergeron et al. 2001). A liver-specific knock out of the AMPKa2 subunit leads to hyperglycemia and a 50% increase in the rate of endogenous glucose production (Andreelli et al. 2006). Leptin and adiponectin do not affect endogenous glucose production in AMPKα2 knockout mice (Andreelli et al. 2006).

We hypothesized that the leptin-mediated attenuation in blood glucose concentrations of STZ-induced diabetic rats is dependent on an intact sympathetic nervous system. To determine whether the sympathetic nervous system plays a role in mediating the ability of central leptin to reduce blood glucose levels in diabetic rats, we chemically denervated the sympathetic nervous system of a group of rats using guanethidine. A control group received injections of vehicle, rather than guanethidine. All rats were made diabetic by STZ treatment and then received daily intracerebroventricular (i.c.v.) injections of either leptin or vehicle. Blood glucose concentrations were measured daily and the norepinephrine content of various tissues was determined at the end of the study. The results suggest that impairment of the sympathetic nervous system does not alter the ability of central leptin administration to reduce blood glucose concentrations in STZ-induced diabetic rats.

Materials and Methods

Animals
Male Wistar rats (~50 g; Harlan Inc., Prattville, AL, USA) were housed in shoebox cages. Rats were kept in a temperature-controlled room with a 12:12 h light-darkness cycle (lights on 0600 h). Rats had free access to chow (Prolab RMH 300, Purina Mills, Richmond, IN, USA) and water. All experimental protocols were approved by Auburn University’s Institutional Animal Care and Use Committee.

Experimental design
Half of the rats were administered guanethidine monosulfate (100 mg/kg; Sigma–Aldrich Co.) s.c. in the area of the back every other day for 2 weeks. The other half of the rats did not receive guanethidine, but did receive control injections of saline. After 2 weeks of injections, rats were allowed to recover. Body weights were determined every other day during the guanethidine injection and recovery periods, and on select days thereafter (prior to STZ injection and prior to killing). Rats were then implanted with an i.c.v. cannula directed into the lateral ventricle (See Cannula placement) and moved to individual hanging cages. All rats were made diabetic by the administration of STZ (see Induction of diabetes). Once hyperglycemia was verified, rats were administrated either i.c.v. leptin (10 μg; Calbiochem, San Diego, CA, USA or R&D Systems Inc., Minneapolis, MN, USA) or vehicle (a 5:3 ratio of 15 mM HCl:7.5 mM NaOH) once daily. Thus, rats were divided into four treatment groups: vehicle–vehicle, vehicle–leptin, guanethidine–vehicle, and guanethidine–leptin. Blood samples were collected daily from the tail vein and blood glucose concentrations were measured (see Blood sampling and glucose determination). In phase 1, i.c.v. leptin was administered daily for 6 consecutive days. After day 6, i.c.v. leptin injections were stopped for 9 days to determine if the effect of leptin on blood glucose concentrations was reversible. In phase 2, daily i.c.v. leptin injections were reinitiated for an additional 6 days. After the experimental period of 21 days, the rats were anesthetized with pentobarbital, and the spleen, brown adipose tissue, white adipose tissue, and liver were collected to determine norepinephrine content. Norepinephrine measurements were used as an indicator of how well guanethidine treatment decreased sympathetic activity.

Cannula placement
Rats were anesthetized by an i.p. injection of ketamine and xylazine (100 mg/kg and 1 mg/kg respectively) and placed in a stereotaxic apparatus. A 22 gauge, stainless steel guide cannula (Plastics One, Roanoke, VA, USA) was implanted into the lateral ventricle (0.8 mm posterior and 1.4 mm lateral to bregma, 3.5 mm ventral to the surface of the skull). Four stainless steel screws and dental cement were used to fix the guide cannula to the skull. A ‘dummy’ cannula 1 mm longer than the guide cannula was placed into the guide cannula. The rats were housed in individual cages and allowed to recover for 4 days. Angiotensin II (40 ng in a total volume of 6 μl; Sigma–Aldrich Co.) was used to verify the accurate placement of the cannula. Rats that drank less than 5 ml of water within 15 min of administration of angiotensin II were excluded from the experiment. After the drinking test, 31 rats were used in this study.

Induction of diabetes
Diabetes was induced with a single i.v. injection of freshly prepared STZ (50 mg/kg; Sigma–Aldrich Co.) in 0.05 M citrate buffer (pH 4.5) via the tail vein. Control rats were injected with citrate buffer only. All STZ-injected rats had blood glucose concentrations greater than 350 mg/dl before the beginning of the leptin injections.

Blood sampling and glucose determination
Blood was sampled via the tail vein. Rats (in the fed state) were held with their tails immersed in warm water (48 °C) for 30–45 s to dilate the vein. A syringe with a 26 gauge needle was then used to withdraw a small amount of blood.
glucose concentrations were determined with an Accu-Chek Active handheld glucometer (Roche Diagnostics).

**Determination of tissue norepinephrine and protein content**

Norepinephrine concentrations were measured by high pressure liquid chromatography (HPLC). Tissues were crushed under liquid nitrogen with a mortar and pestle. About 100 mg of sample was placed in pre-weighed microcentrifuge tubes. A cold solution containing 0.2 M perchloric acid and 1 ng/ml ascorbic acid (PCA/AA, 790 μl) was added and this mixture was sonicated thrice (10–30 s each time) on ice. Ten microliters of an internal standard, 3,4-dihydroxybenzylamine hydrobromide (Sigma–Aldrich Co.) were added. The solution (800 μl) was mixed and centrifuged at 9300 g for 10 min. The supernatant (600 μl) was added to a tube containing 200 mg alumina, which was then mixed with 1 ml 0.5 M Tris–HCl (pH 8.6) and centrifuged at 9300 g for 1 min. The supernatant was removed and discarded, and the alumina was washed twice by mixing with 1 ml water followed by centrifugation for 1 min at 9300 g. After removing all of the supernatant, catecholamines were eluted from the alumina by mixing with 300 μl PCA/AA followed by centrifugation for 1 min at 9300 g. The PCA/AA supernatant (~300 μl), which contained the catecholamines, was transferred to vials suitable for HPLC analysis. The tissue extracts and standards (10 μl) were processed by HPLC using a Gynkotek HPLC pump (P580: Gynkotek GmbH, Munich, Germany) and HPLC autosampler (Model GINA 50) attached to a Hewlett-Packard Zorbax SB-C18 Stable Analytical Column (4.6×250 mm, 5-micron) pre-equilibrated with citric acid buffer (21.01 g citrate, 245 mg sodium octyl sulfate per liter, 10% ethanol, pH 4) at 0.7 ml/min. The samples were analyzed at 50 nA for 15 min with a Decade digital electrochemical amperometric detector and VT-03 electrochemical flow cell (both from Gynkotek). The data were collected using the Chromeleon chromatography information management system (Gynkotek) and a Gateway PC computer. Protein concentrations were determined by the Bio-Rad protein assay (Bio-Rad Laboratories, Inc). Norepinephrine content was expressed as ng per mg protein.

**Statistical analysis**

All results are presented as means ± S.E.M. Statistical analyses were performed using SPSS 12.0 (SPSS Inc., Chicago, IL, USA) and SAS 8.02 (SAS Institute Inc., Cary, NC, USA) or JMP IN 5.1.2. (SAS Institute Inc). Repeated-measures ANOVA was used to determine the effects of guanethidine and leptin treatment on blood glucose concentrations and the effects of guanethidine treatment on body weight. A one-way ANOVA was used to determine the effect of guanethidine treatment on blood glucose concentrations, prior to making the rats diabetic and after making them diabetic, but prior to central leptin administration. Two-way ANOVA was used to determine the main effects of guanethidine and leptin treatment and their interaction on norepinephrine content within the various tissues. Contrast statements or least-squares Student’s *t*-tests were used as a follow-up test to compare individual groups. A difference of *P*≤0.05 was considered statistically significant.

**Results**

**Effects of guanethidine and leptin treatment on body weight**

Guanethidine treatment resulted in a decrease in body weight (Fig. 1A). Across the period of guanethidine treatment and
recovery, guanethidine–treated rats had lower body weights ($P=0.0006$) than untreated rats. This became a statistically significant difference by day 12 after guanethidine injections began. The difference in body weights reached ~10% and was maintained even after guanethidine injections ceased through the time rats were made diabetic by the injection of STZ.

Induction of diabetes caused a significant decrease in body weight (~40 g) over a period of 3 weeks (Fig. 1B). The diabetes–induced decrease in body weight was significantly attenuated by the prior treatment of guanethidine ($P=0.007$). Leptin treatment appeared to also attenuate the diabetes–induced decrease in body weight, though this did not quite reach statistical significance ($P=0.08$). The combination of prior treatment with guanethidine and daily i.c.v. leptin injections prevented the diabetes–induced decrease in body weight, such that body weight remained essentially unchanged over the 3-week period.

**Effect of guanethidine and central leptin on blood glucose concentration**

Before diabetes was induced and immediately after induction (i.e., prior to central leptin administration), there were no differences in blood glucose concentrations between rats previously treated with guanethidine and control animals (Fig. 2). Prior to the induction of diabetes, both groups of rats had blood glucose concentrations around 120 mg/dl. The day after treatment with STZ, the blood glucose concentration of the guanethidine–treated and control rats averaged 460 ± 18 and 495 ± 16 mg/dl respectively. Daily central leptin administration decreased blood glucose concentrations by day 4 in both guanethidine–treated and control animals. The leptin–induced decrease continued through day 7. Considering days 4–7, there was an effect of leptin ($P<0.0001$), time ($P=0.005$), and an interaction between these two factors ($P<0.0001$). Though there was no interaction between guanethidine and leptin, the guanethidine, leptin–treated rats had lower blood glucose concentrations than control, leptin–treated rats ($P=0.014$) on days 6 and 7. After discontinuing central leptin treatment for 9 days (day 16), blood glucose concentrations increased toward the high levels maintained by the diabetic non–leptin–treated rats. The blood glucose concentrations of control, leptin–treated rats increased to levels that were not statistically different from the values obtained from rats previously receiving i.c.v. vehicle injections. However, blood glucose concentrations of guanethidine–treated rats previously treated with leptin were still lower than those of the other groups. The second round of leptin injections again decreased blood glucose concentrations in both vehicle– and guanethidine–treated animals. Considering days 16–22, there was a decrease in blood glucose concentrations in rats treated with leptin ($P<0.0001$). There was also an effect of time ($P=0.001$) and an interaction between the effect of leptin and time ($P=0.035$). In addition, there was an overall effect of guanethidine treatment ($P=0.035$) to lower blood glucose concentrations in leptin–treated animals. Over this 6-day injection period, guanethidine administered leptin–treated rats had lower blood glucose concentrations than did vehicle administered leptin–treated rats ($P=0.013$). During this period, blood glucose concentrations were not different between guanethidine and vehicle previously administered vehicle–treated rats.

**Norepinephrine content in tissues**

Guanethidine treatment decreased norepinephrine content in spleen ($P<0.001$; Fig. 3), brown adipose tissue ($P<0.001$; Fig. 4), and white adipose tissue ($P=0.034$; Fig. 5). However, previous treatment with guanethidine did not have an effect on norepinephrine content in the liver (Fig. 6). The average decrease in norepinephrine content due to guanethidine treatment was 65, 61, and 85%, for the spleen, brown adipose tissue, and white adipose tissue respectively. In the liver, there was an overall effect for norepinephrine content to be greater in leptin–treated rats than in rats not treated with leptin ($P=0.001$). An interaction between guanethidine and leptin treatments that approached statistical significance ($P=0.07$) suggests this result was mostly due to the effect of leptin in guanethidine–treated rats. Daily leptin treatment had no significant effect on norepinephrine content in any other tissue tested.
Discussion

Our hypothesis that prior guanethidine treatment would block or attenuate the ability of central leptin administration to decrease blood glucose concentrations in diabetic rats was not supported by the results. Both guanethidine-treated and vehicle-treated diabetic rats responded to i.c.v. leptin with an attenuation of blood glucose concentrations. An analysis of the tissue norepinephrine content suggested that the prior guanethidine treatment was effective at suppressing sympathetic activity in most of the tissues examined. Brown adipose tissue, white adipose tissue, and spleen, all showed a guanethidine-related decrease in norepinephrine content. Average norepinephrine content remaining in these tissues of guanethidine-treated rats ranged from 15 to 39% of control values; however, the norepinephrine content of the liver was not affected by prior guanethidine treatment. This contrasts with the findings of Villanueva et al. (2003) who reported that guanethidine-treated rats have less than 3% of the liver norepinephrine content of control animals. This difference is most likely accounted for by either differences in the age of the animals when guanethidine was first introduced or in the route of administration or both. In the present study, guanethidine was injected s.c. (subQ) beginning when the rats were just over 3 weeks of age (body weight ~50 g),
Figure 6 Norepinephrine content in the liver (ng/mg protein). Wistar rats were pretreated every other day with either guanethidine (guan) (100 mg/kg) or vehicle (veh) for 2 weeks. Rats were then implanted with a cannula directed into the lateral ventricle, made diabetic with an i.v. injection of streptozotocin (50 mg/kg), and treated daily with either leptin (10 μg) or vehicle (veh). At the end of the experimental period, rats were anesthetized with pentobarbital and livers were collected and frozen in liquid nitrogen for subsequent norepinephrine and protein determinations. Results are shown as means ± S.E.M. Group means represent between 6 and 11 observations. Means with different letters indicate statistically significant differences (P<0.05).

whereas Villanueva et al. administered guanethidine via an i.p. route when the rats were 6 days old. Neonatal animals are more sensitive to the effects of guanethidine than older animals (Johnson & O’Brien 1976) and an i.p. route of administration might be expected to affect the liver more than a subQ route.

There are three possible interpretations of the present data: 1) The sympathetic nervous system does not mediate leptin’s ability to normalize blood glucose concentrations in STZ-induced diabetic rats, 2) The sympathetic nervous system is involved in leptin’s ability to normalize blood glucose concentrations, but only a small fraction of the total sympathetic activity is enough to have the full effect, and 3) The sympathetic nervous system is required to mediate the effects of leptin, but it only involves tissues that are not affected by guanethidine treatment (e.g., liver, as shown herein). Others have found that α1, β1, β2, or β3 adrenergic receptor blockade did not affect the ability of centrally administered leptin to normalize blood glucose concentrations in STZ-induced diabetic rats (da Silva et al. 2006). However, the combination of α1, β1, and β2 adrenergic receptor blockade did attenuate the leptin-induced rise in heart rate. Therefore, the present results, using guanethidine treatment, and the findings of da Silva et al. (2006), using adrenergic receptor antagonists, both suggest that the sympathetic nervous system is not required for centrally administered leptin to lower the blood glucose concentrations of STZ-induced diabetic rats.

In our previous studies and those of others, chronic central leptin administration normalized blood glucose concentrations of diabetic rats within several days and blood glucose remained at normal levels until the end of the study (Lin et al. 2002, da Silva et al. 2006, White & Wernette unpublished observations). In the present study, we stopped the daily injections of leptin after day 7 and found that the blood glucose concentrations of the rats previously injected with leptin increased between days 7 and 16, indicating that the blood glucose lowering effect of leptin is reversible. Resuming the daily leptin injections on day 16 once again resulted in a decrease in the blood glucose concentrations of the diabetic rats. To our knowledge, the reversibility of the glucose lowering effect of i.c.v. leptin has not been demonstrated previously.

Guanethidine pretreatment accentuated the ability of leptin to decrease blood glucose concentrations over time. This was not manifested until the last 2 days of the first set of leptin injections (phase 1). However, this accentuation carried over through the period of recovery from leptin injection and throughout the second set of leptin injections (phase 2). Guanethidine treatment in the absence of leptin administration had no effect on blood glucose concentrations. This means that blood glucose concentrations are significantly lower in response to central leptin administration in the absence of a fully functional sympathetic nervous system. This suggests that some aspect of sympathetic nervous activity increases blood glucose concentrations in leptin-treated rats. While it is beyond the scope of this study to address the cause, sympathetic stimulation is thought to increase hepatic glucose production (Nonogaki 2000), which would tend to increase blood glucose concentrations in rats not pretreated with guanethidine. The effect of the sympathetic nervous system on hepatic glucose production appears to be mediated through a combination of direct innervation of the liver, epinephrine from the adrenal medulla, and glucagon from the pancreas (Nonogaki 2000). However, we did not observe a decrease in the norepinephrine content from livers of guanethidine-treated rats in the present study and guanethidine treatment does not affect epinephrine release from the adrenal medulla (Johnson et al. 1975).

In nondiabetic rats, pretreatment with guanethidine has been found to enhance the reduction in food intake caused by leptin by about 20% (Dobbins et al. 2002). Though food intake was not determined in the present study, it is possible that a decrease in food intake could have accentuated the leptin-induced decrease in the blood glucose concentrations that we found in rats pretreated with guanethidine. However, since this guanethidine–related decrease in blood glucose was observed even after leptin injections had been terminated for 9 days, it could also be related to factors other than a decrease in food intake. It is important to note that the leptin-induced decrease in blood glucose concentrations of diabetic rats is not due to a decrease in food intake. We and others have previously shown that pair-feeding nondiabetic or diabetic rats to the amount eaten by leptin-treated rats does not result
Further research is needed to elucidate the mechanism by which centrally administered leptin normalizes or attenuates blood glucose concentrations in STZ-induced diabetic rats.

Declaration of interest

There is no conflict of interest that would prejudice its impartiality.

Funding

This work was financially supported by a BioGrant from Auburn University.

References


Received in final form 4 June 2008
Accepted 3 July 2008
Made available online as an Accepted Preprint 3 July 2008